Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Erik Briers
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic hormone-sensitive and castration-resistant prostate cancer (PCa).
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients
|
Abstract Fatigue is a common symptom of cancer patients, which can impair quality of life even years after treatment. Little is known about genetic determinants of fatigue, especially in prostate cancer (PCa). This study aims to identify SNPs associated with long-term fatigue in a prospective cohort of PCa patients. A genome-wide association study was conducted in non-metastatic PCa patients treated with radiotherapy in 7 European countries and the USA.
By Philipp Heumann, Miguel E. Aguado-Barrera, David Azria, Erik Briers, Jenny Chang-Claude, Ananya Choudhury, Alison Dunning, Laura Fachal, Antonio Gomez-Caamano, Sara Gutiérrez-Enríquez, Rudolf Kaaks, Sarah L. Kerns, Barry Rosenstein, Dirk De Ruysscher, Martina Schmidt, Elena Sperk, Hilary Stobart, Marlon R. Veldwijk, Tim Ward, Adam Scott Webb, Catharine West, Tiziana Rancati, Tim Rattay, Christopher Talbot, Petra Seibold, Harkeran K. Jandu, Olivia Fuentes-Ríos, Maarten Lambrecht, R. Paul Symonds, Liv Veldeman
|
Nature
Verified
Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes
Get full text access Log in, subscribe or purchase for full access. References 1. Elendu, C. ∙ Okahia, T.W. ∙ Blewusi, G.S. ... FDA approves Veozah (fezolinetant) for menopausal symptoms: a new nonhormonal option Ann Med Surg. 2025; 87:5373-5377 2. Gillessen, S. ∙ Turco, F. ∙ Davis, I.D. ... Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) Eur Urol. 2025; 87:157-216 3. Lin, K.L. ∙ Talmor, B. ∙ Crumbaker, M. ...
SPARC: The Importance for Patients with Prostate Cancer
Get full text access Log in, subscribe or purchase for full access. References 1. Herrmann K, Walz J, McLennan S, et al. SPARC: the Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: a Delphi analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.005. 2. Miyahira, A. ∙ Soule, H.
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Abstract In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: “PCa”, “screening”, and “cost effectiveness”.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Abstract The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Abstract The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa).
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Abstract The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa).
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Mottet N. Bellmunt J. Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017; 71: 618-629 Mottet N. Cornford P. van den Bergh R.C.N. et al. EAU - EANM - ESTRO - ESUR - SIOG guidelines on prostate cancer. European Association of Urology Guidelines Office, Arnhem, The Netherlands2020 Guyatt G.H. Oxman A.D. Kunz R. et al. Going from evidence to recommendations. BMJ. 2008; 336: 1049-1051 Arnold M.
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Cornford P. Bellmunt J. Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017; 71: 630-642 Mottet N., van den Bergh R., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. In press. Guyatt G.H. Oxman A.D. Vist G.E. Kunz R. et al.
Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position
Publication HistoryPublished online: September 17, 2018Accepted: August 30, 2018;
Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91 - European Urology
We would like to raise some issues concerning the article by van der Poel et al. [1x[1]van der Poel, H.G., van den Bergh, R.C.N., Briers, E. et al. Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. 2018; 74: 84–91Google ScholarSee all References][1].First, this paper seems to reflect only their position as we find no evidence that the authors sought to investigate the opinion of the European Association of Urology (EAU).
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018
Jump to Section1. Introduction2. Patient selection3. Techniques of FT 3.1. Focal cryosurgery ablation of the prostate 3.2. Focal HIFU 3.3. Irreversible electroporation and radiofrequency ablation 3.4. Focal laser ablation 3.5. Photodynamic focal therapy 3.6. Focal brachytherapy4. Statements 4.1. Can FT treat the tumour cell clones most likely to metastasise? 4.2. What is the evidence regarding the clinical effectiveness of FT for localised PCa?
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
To present a summary of the 2016 version of the European Association of Urology (EAU) – European Society for Radiotherapy & Oncology (ESTRO) – International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). The working panel performed a literature review of the new data (2013–2015).
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). The working panel performed a literature review of the new data (2013–2015).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Erik
Contact Erik, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack